Pyridine Ruthenium(III) complexes entrapped in liposomes with enhanced cytotoxic properties in PC-3 prostate cancer cells

作者: Angela D'Amora , Maria Elena Cucciolito , Roberta Iannitti , Giancarlo Morelli , Rosanna Palumbo

DOI: 10.1016/J.JDDST.2019.02.009

关键词:

摘要: Abstract The first aim of the present study is development a new ruthenium(III) complex, belonging to NAMI-A class, with potentially high cytotoxic ability. presence fully protected sugar moiety as ruthenium ligand should increase complex ability cross cellular membranes. Furthermore, it sets this molecule in area biocompatible agents tumor drug. second, more relevant, purpose verify complexes activity after loading into liposomes. We reported characterization and vitro biological assays pyridine derivatives loaded Egg l -α-phosphatidylcholine cholesterol/DSPE-PEG Dynamic light scattering estimates that sizes all obtained liposomes are 100 nm range. This value suitable for vivo use. release kinetic allowed selecting best ratio between lipid fraction metal be tested experiments. growth inhibitory effects both liposomal free PC-3 prostate cancer cell lines demonstrate liposome entrapped (III) suggesting additional role further antimetastatic function.

参考文章(52)
G. Sava, I. Capozzi, K. Clerici, G. Gagliardi, E. Alessio, G. Mestroni, PHARMACOLOGICAL CONTROL OF LUNG METASTASES OF SOLID TUMOURS BY A NOVEL RUTHENIUM COMPLEX Clinical & Experimental Metastasis. ,vol. 16, pp. 371- 379 ,(1998) , 10.1023/A:1006521715400
Domenica Musumeci, Lucia Rozza, Antonello Merlino, Luigi Paduano, Tiziano Marzo, Lara Massai, Luigi Messori, Daniela Montesarchio, Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems Dalton Transactions. ,vol. 44, pp. 13914- 13925 ,(2015) , 10.1039/C5DT01105A
Teni Boulikas, Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opinion on Investigational Drugs. ,vol. 18, pp. 1197- 1218 ,(2009) , 10.1517/13543780903114168
Seiji Komeda, Angela Casini, Next-generation anticancer metallodrugs Current Topics in Medicinal Chemistry. ,vol. 12, pp. 219- 235 ,(2012) , 10.2174/156802612799078964
Aldrik H. Velders, Alberta Bergamo, Enzo Alessio, Ennio Zangrando, Jaap G. Haasnoot, Claudia Casarsa, Moreno Cocchietto, Sonia Zorzet, Gianni Sava, Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). Journal of Medicinal Chemistry. ,vol. 47, pp. 1110- 1121 ,(2004) , 10.1021/JM030984D
Aviva Levina, Anannya Mitra, Peter A. Lay, Recent developments in ruthenium anticancer drugs. Metallomics. ,vol. 1, pp. 458- 470 ,(2009) , 10.1039/B904071D
Mimi Liu, Zhi Jun Lim, Yee Yen Gwee, Aviva Levina, Peter A. Lay, Characterization of a Ruthenium(III)/NAMI‐A Adduct with Bovine Serum Albumin that Exhibits a High Anti‐Metastatic Activity Angewandte Chemie. ,vol. 49, pp. 1661- 1664 ,(2010) , 10.1002/ANIE.200906079
Samuel M Meier, Maria Novak, Wolfgang Kandioller, Michael A Jakupec, Vladimir B Arion, Nils Metzler‐Nolte, Bernhard K Keppler, Christian G Hartinger, None, Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate. Chemistry: A European Journal. ,vol. 19, pp. 9297- 9307 ,(2013) , 10.1002/CHEM.201300889
Gianni Sava, Sabrina Pacor, Giovanni Mestroni, Enzo Alessio, Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clinical & Experimental Metastasis. ,vol. 10, pp. 273- 280 ,(1992) , 10.1007/BF00133563